Arylamine N-acetyltransferases: Genetic polymorphism and susceptibility to xenobiotics;LES ARYLAMINE N-ACETYLTRANSFERASES: DU POLYMORPHISME GENETIQUE A LA SUSCEPTIBILITE AUX XENOBIOTIQUES

Medecine/Sciences

Volumn 14, Issue 1, 1998, Pages 27-36

  Deloménie, Claudine ^a   Grant, Denis M ^b   Krishnamoorthy, Rajagopal ^a   Dupret, Jean Marie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DRUG METABOLIZING ENZYME; XENOBIOTIC AGENT;

ACETYLATOR PHENOTYPE; BIOTRANSFORMATION; CANCER SUSCEPTIBILITY; CHROMOSOME 8P; DRUG METABOLISM; ENZYME POLYMORPHISM; GENE EXPRESSION; GENETIC POLYMORPHISM; INTESTINE; LIVER; PHARMACOGENETICS; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0031983614     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/880     Document Type: Review

References (41)

1. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997 ; 37 : 269-96.
2. Nebert DW. Polymorphisms in drug-metabolizing enzymes : what is their clinical relevance and why do they exist? Am J Hum Genet 1997 ; 60 : 265-71.
3. Evans DAP. N-acetyltransferase. In : Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York : Pergamon Press, 1992 : 95-178.
4. Grant DM, Mörike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990 ; 85 : 968-72.
5. Larrey D. Polymorphisme génétique du métabolisme hépatique des médicaments. Med Sci 1986 ; 2 : 364-72.
6. Beaune P. Les cytochromes p450 hépatiques humains. Med Sci 1986 ; 2 : 358-63.
7. Rieder MJ, Shear NH, Kanee A, Tang BK. Predominance of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991 ; 49 : 13-7.
8. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases : a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991 ; 39 : 184-91.
9. Ilett KF, Ingram DM, Carpenter DS, Teilett CH, Lang NP, Kadlubar FF, Minchin RF. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 1994 ; 47 : 914-7.
10. Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cylochem 1996 ; 44 : 1059-67.
11. Cribb AE, Grant DM, Miller MA, Spielberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Ther 1991 ; 259 : 1241-6.
12. Derewlany LO, Knie B, Koren G. Arylamine N-acetyltransferase activity of the human placenta. J Pharmacol Exp Ther 1994 ; 269 : 756-60.
13. Sadrieh N, Davis CD, Snyderwine EG. N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res 1996 ; 56 : 2683-7.
14. Hickman D, Risch A, Buckle V, Spurr NK, Jeremiah SJ, McCarthy A, Sim E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994 ; 297 : 441-5.
15. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yasuschi Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995 ; 5 : 1-17.
16. Pacifici GM, Bencini C, Rane A. Acetyltransferase in humans : development and tissue distribution. Pharmacology 1986 ; 32 : 283-91.
17. 68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem 1992 ; 267 : 7381-5.
18. 64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem J 1997 ; 323 : 207-15.
19. Dupret JM, Goodfellow GH, Janezic SA, Grant DM. Structure-function studies of human N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in E. Coli. J Biol Chem 1994 ; 269 : 26830-5.
20. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984 ; 17 : 459-64.
21. Deloménie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996 ; 6 : 177-85.
22. Grant DM, Vohra P, Avis Y, Ima A. Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe. J Basic Clin Physiol Pharmacol 1992 ; 3 (suppl) : 244.
23. Wolkenstein P, Carrière V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995 ; 5 : 255-8.
24. Deloménie C, Grant D, Mathelier-Fusade P, Jacomet C, Leynadier F, Jacqz-Aigrain E, Rozenbaum W, Krishnamoorthy R, Dupret JM. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 1994 ; 38 : 581-2.
25. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992 ; 54 : 17-61.
26. d'Errico A, Taioli E, Chen X, Vineis P. Genetic metabolic polymorphisms and the risk of cancer : a review of the literature. Biomarkers 1996 ; 1 : 149-73.
27. Grant DM, Josephy PD, Lord HL, Morrison LD. Salmonella typhimurium strains expressing human arylamine N-acetyltransferases : metabolism and mutagenic activation of aromatic amines. Cancer Res 1992 ; 52 : 3961-4.
28. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993 ; 14 : 1633-8.
29. Probst MR, Blum M, Fasshauer I, D'Orazio D, Meyer UA, Wild D. The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo(4,5-f) quinoline (IQ). Carcinogenesis 1992 ; 13 : 1713-7.
30. Guengerich FP, Gillam EMJ, Shimada T. New applications of bacterial systems to problems in toxicology. Crit Rev Toxicol 1996 ; 26 : 551-83.
31. Hein DW, Rustan TD, Ferguson RJ, Doll MA, Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994 ; 68 : 129-33.
32. Minchin RF. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem J 1995 ; 307 : 1-3.
33. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991 ; 50 : 573-9.
34. Brockmöller J, Cascorbi I, Kerb R, Roots, I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996 ; 56 : 3915-25.
35. Agundez JAG, Oliveira M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benitez J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996 ; 6 : 501-12.
36. Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 1996 ; 95 : 2981-3.
37. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA, Harrington AM, Shields PG. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996 ; 276 : 1494-1501.
38. Orzechowska-Juzwenko K, Milejski P, Patkowski J, Nittner-Marszalska M, Malolepszy J. Acetylator phenotype in patients with allergic diseases and its clinical significance. Int J Clin Pharmacol Ther Toxicol 1990 ; 28 : 420-5.
39. Roberts-Thomson IC, Ryan P, Khoo KK, Hart WJ, McMichael AJ, Butler RN. Diet, acetylatbr phenotype, and risk of colorectal neoplasia. Lancet 1996 ; 347 : 1372-4.
40. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996 ; 56 : 3961-6.
41. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993 ; 3 : 45-50.